logo
Synthetic Human Genome Project gets go ahead

Synthetic Human Genome Project gets go ahead

BBC News26-06-2025
Work has begun on a controversial project to create the building blocks of human life from scratch, in what is believed to be a world first.The research has been taboo until now because of concerns it could lead to designer babies or unforeseen changes for future generations.But now the World's largest medical charity, the Wellcome Trust, has given an initial £10m to start the project and says it has the potential to do more good than harm by accelerating treatments for many incurable diseases.Dr Julian Sale, of the MRC Laboratory of Molecular Biology in Cambridge, who is part of the project, told BBC News the research was the next giant leap in biology."The sky is the limit. We are looking at therapies that will improve people's lives as they age, that will lead to healthier aging with less disease as they get older."We are looking to use this approach to generate disease-resistant cells we can use to repopulate damaged organs, for example in the liver and the heart, even the immune system," he said.But critics fear the research opens the way for unscrupulous researchers seeking to create enhanced or modified humans.Dr Pat Thomas, director of the campaign group Beyond GM, said: "We like to think that all scientists are there to do good, but the science can be repurposed to do harm and for warfare".Details of the project were given to BBC News on the 25th anniversary of the completion of the Human Genome Project, which mapped the molecules in human DNA and was also largely funded by Wellcome.
Every cell in our body contains a molecule called DNA which carries the genetic information it needs. DNA is built from just four much smaller blocks referred to as A, G, C and T, which are repeated over and over again in various combinations. Amazingly it contains all the genetic information that physically makes us who we are.The Human Genome Project enabled scientists to read all human genes like a bar code. The new work that is getting under way, called the Synthetic Human Genome Project, potentially takes this a giant leap forward – it will allow researchers not just to read a molecule of DNA, but to create parts of it – maybe one day all of it - molecule by molecule from scratch.
The scientists' first aim is to develop ways of building ever larger blocks of human DNA, up to the point when they have synthetically constructed a human chromosome. These contain the genes that govern our development, repair and maintenance.These can then be studied and experimented on to learn more about how genes and DNA regulate our bodies.Many diseases occur when these genes go wrong so the studies could lead to better treatments, according to Prof Matthew Hurles, director of the Wellcome Sanger Insititute which sequenced the largest proportion of the Human Genome."Building DNA from scratch allows us to test out how DNA really works and test out new theories, because currently we can only really do that by tweaking DNA in DNA that already exists in living systems".
The project's work will be confined to test tubes and dishes and there will be no attempt to create synthetic life. But the technology will give researchers unprecedented control over human living systems.And although the project is hunting for medical benefits, there is nothing to stop unscrupulous scientists misusing the technology. They could, for example, attempt to create biological weapons, enhanced humans or even creatures that have human DNA, according to Prof Bill Earnshaw, a highly respected genetic scientist at Edinburgh University who designed a method for creating artificial human chromosomes."The genie is out of the bottle," he told BBC News. "We could have a set of restrictions now, but if an organisation who has access to appropriate machinery decided to start synthesising anything, I don't think we could stop them"Ms Thomas is concerned about how the technology will be commercialised by healthcare companies developing treatments emerging from the research."If we manage to create synthetic body parts or even synthetic people, then who owns them. And who owns the data from these creations? "Given the potential misuse of the technology, the question for Wellcome is why they chose to fund it. The decision was not made lightly, according to Dr Tom Collins, who gave the funding go-ahead."We asked ourselves what was the cost of inaction," he told BBC News."This technology is going to be developed one day, so by doing it now we are at least trying to do it in as responsible a way as possible and to confront the ethical and moral questions in an upfront way as possible".A dedicated social science programmewill run in tandem with the project's scientific development and will be led by Prof Joy Zhang, a sociologist, at the University of Kent."We want to get the views of experts, social scientists and especially the public about how they relate to the technology and how it can be beneficial to them and importanlty what questions and concerns they have," she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pharmacy warning of unsustainable demand for weight loss medication
Pharmacy warning of unsustainable demand for weight loss medication

The Independent

time13 minutes ago

  • The Independent

Pharmacy warning of unsustainable demand for weight loss medication

The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

Roche to investigate whether new drug can delay or prevent Alzheimer's disease
Roche to investigate whether new drug can delay or prevent Alzheimer's disease

Reuters

time44 minutes ago

  • Reuters

Roche to investigate whether new drug can delay or prevent Alzheimer's disease

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.

Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports

Reuters

time2 hours ago

  • Reuters

Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store